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OBJECTIVE—To study the role of the ENPP1 Q121 variant on
glucose homeostasis in whites from Italy.
RESEARCH DESIGN AND METHODS—We conducted case-
control studies in 764 adults (from two independent samples of
289 nonobese and 485 obese individuals) and 240 overweight/
obese children undergoing oral glucose tolerance testing
(OGTT). Early-phase insulin secretion and insulin sensitivity (the
insulinogenic index and the insulin sensitivity index) and their
interplay (the disposition index) were calculated.
RESULTS—In adult subjects, glucose proﬁles during OGTT
were signiﬁcantly (P  2  10
2) different across K121Q
genotype groups and higher in QQ than KK individuals (P  5 
10
2). The insulinogenic index was signiﬁcantly reduced in QQ
(18.5  3.4) compared with both KK (31.6  1.0; P  2.2  10
7)
and KQ (30.5  1.5; P  3.2  10
6) individuals. KQ individuals
also showed a reduced insulin sensitivity index compared with
KK subjects (P  3.6  10
2). The disposition index was lower
in QQ carriers than in KQ and KK individuals (P  8  10
3 and
4  10
4, respectively) and lower in KQ than in KK individuals
(P  3  10
2). Data obtained in overweight/obese children were
very similar to those observed in adults, with QQ individuals
showing (compared with KQ and KK subjects) a reduced insuli-
nogenic index (P  7  10
3 and 2  10
2, respectively) and
disposition index (P  2  10
2 and 7  10
3, respectively).
CONCLUSIONS—Homozygous carriers of the ENPP1 Q121
variant are characterized by an altered glucose homeostasis.
Reduced early-phase insulin secretion and inefﬁcient interplay
between insulin secretion and sensitivity, which occur at early
ages, are major determinants of this defect. Diabetes 57:
3360–3364, 2008
I
nsulin resistance and inadequate insulin secretion
are pathogenic for type 2 diabetes (1). Insulin-
resistant subjects who eventually develop type 2
diabetes maintain normal or near-normal glycemia
for many years because of compensatory hyperinsulin-
emia (2). Type 2 diabetes eventually ensues only when
-cells fail to secrete sufﬁcient insulin to adequately coun-
teract insulin resistance (3). Thus, an inefﬁcient interplay
between insulin secretion and sensitivity is the key patho-
genic factor for developing type 2 diabetes. In agreement
with this tenet, the disposition index (the product of
insulin secretion  insulin sensitivity) is the best predictor
of type 2 diabetes (4).
Ectonucleotide pyrophosphatase phosphodiesterase 1
(ENPP1) (5) downregulates insulin signaling by direct
inhibition of insulin receptor signaling (6–8). We previ-
ously described an ENPP1 missense polymorphism
(K121Q, rs1044498) (9). Compared with the more common
K121, the Q121 variant is a stronger inhibitor of insulin
receptor signaling in cultured cells (7,9) and has been
associated in most, although not all, studies with insulin
resistance–related abnormalities (5,6). Several groups
have investigated whether the Q121 variant is also associ-
ated with type 2 diabetes (5,6). Although results have not
been homogeneous across studies, a recent and compre-
hensive meta-analysis has concluded that Europeans who
are homozygous for the Q121 allele (i.e., carrying the QQ
genotype) have a 38% increased risk of type 2 diabetes
(10). More recently, the Q121 allele has been reported to
be associated with hyperglycemia and insulin resistance in
2,511 Framingham Heart Study participants (11). To gain
insight about the mechanisms underlying these associa-
tions, we studied insulin secretion, insulin sensitivity, and
their interplay in whites from Italy across ENPP1 K121Q
genotype groups.
RESEARCH DESIGN AND METHODS
A total of 764 adult (age 18–70 years) and 240 child (age 8–17 years) unrelated
subjects from Eastern Sicily, with fasting plasma glucose 7.0 mmol/l and not
taking medications known to interfere with glucose and lipid metabolism,
were recruited at the Endocrine Unit of Garibaldi Hospital (Catania, Italy) (see
Methods in the online appendix [available at http://dx.doi.org/10.2337/db07-
1830] for details of their clinical characteristics, the study design, and oral
glucose tolerance testing [OGTT]-derived measurements). People from East-
ern Sicily have been reported to be genetically homogeneous (12), which is a
feature that minimizes the risk of population stratiﬁcation.
The study protocol was approved by the institutional review board and
performed according to the dictates of the Helsinki Declaration. Written
informed consent was obtained from each adult participant and from a parent
of each child.
Genotyping. DNA was extracted from whole blood by standard methods.
Genotyping was performed by restriction fragment–length polymorphism (9),
with a failure rate 1%. Genotyping quality was checked by directly sequenc-
ing 10% of randomly selected samples. The agreement rate of resequenced
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3360 DIABETES, VOL. 57, DECEMBER 2008samples was 99%. The proportion of the K121Q genotypes was in Hardy-
Weinberg equilibrium in both samples studied.
Statistical analysis. Data are provided as means  SEM. All the analyses are
adjusted for age, sex, and BMI. Continuous variables were compared between
groups using one-way or repeated-measurements ANCOVA. In particular,
repeated-measurements ANCOVA models to assess differences over time were
carried out via hierarchical linear models, and within-patient correlation was
accounted for with an unstructured correlation type matrix (13). Simple and
multiple regression models were used to test for correlations between
continuous variables. The interaction between genotype and BMI in modulat-
ing OGTT-derived indexes was tested by the general linear model analysis
after adjusting for age and sex. 
2 was used to test for association between
categorical variables and genotypes and to test the Hardy-Weinberg equilib-
rium as well. Variables not normally distributed were log transformed for
analyses. A P value 0.05 was considered signiﬁcant. All analyses were
performed using SPSS (version 15.0; SPSS, Chicago, IL) and SAS (release 9.1;
SAS Institute, Cary, NC).
RESULTS
Adult subjects
Baseline characteristics. Clinical baseline characteris-
tics of nonobese and obese subjects pooled together and
stratiﬁed according to the ENPP1 K121Q genotype are
shown in Table 1. Fasting plasma glucose was associated
with the Q121 variant and was higher in QQ individuals.
Data are also given separately for nonobese and obese
individuals (Table 1 of the online appendix).
Glucose and insulin proﬁles during OGTT. In both
nonobese and obese individuals, plasma glucose levels
tended to be different across genotype groups, with QQ
carriers showing the worst proﬁle (Fig. 1A and B, respec-
tively in the online appendix), which reached statistical
signiﬁcance in the obese group (age-, sex-, and BMI-
adjusted overall P value 4.8  10
2). Because glucose
proﬁles across genotypes were similar in the two groups,
data were pooled and analyzed together. Plasma glucose
levels during OGTT were different across genotypes (ad-
justed overall P value 2  10
2) (Fig. 1A). At post hoc
analysis, the glucose proﬁle was higher in QQ than in KK
carriers (adjusted P  5  10
2). Although no signiﬁcant
difference was observed in insulin proﬁles across geno-
type groups, a clear genotype-time interaction was ob-
served (adjusted P  2.6  10
3) (Fig. 1B). As a matter of
fact, plasma insulin levels at 30 min were lower in QQ than
in KQ (adjusted P  2  10
4) and KK (adjusted P  4 
10
5) carriers.
Insulin secretion and sensitivity. First-phase insulin
secretion, as indicated by the insulinogenic index, was
different across genotypes (adjusted overall P value 1.2 
10
6) (Fig. 1C). At post hoc analysis, the insulinogenic
index was reduced in QQ (18.5  3.4) compared with KK
(31.6  1.0; adjusted P  2.2  10
7) and KQ (30.5  1.5;
adjusted P  3.2  10
6) individuals. The insulin sensitiv-
ity index was different across genotypes (adjusted overall
P value 5  10
3). At post hoc analysis, insulin sensitivity
index was reduced in KQ (4.3  0.2; adjusted P  3.6 
10
2) but not QQ individuals (5.1  1.1) compared with
that of KK (4.9  0.2) subjects (Fig. 1D). The disposition
index was different across genotypes (adjusted overall P
value 7.9  10
5). At post hoc analysis, the disposition
index was lower in KQ (142.9  13.4) and QQ (97.2  28.7)
compared with that of KK (166.6  9.8) individuals (ad-
justed P  3  10
2 and 4  10
4, respectively) and
lower in QQ than in KQ individuals (adjusted P  8 
10
3) (Fig. 1E).
Gene-BMI interaction. In the whole sample, insulin
sensitivity index was inversely related to BMI ( value for
log-transformed BMI 8.40; P  1  10
10). The linear
slope was steeper in QQ ( 11.68) than in KK (
8.95) or KQ ( 6.86) individuals, indicating a gene-
BMI interaction (age- and sex-adjusted P  5.6  10
3)i n
modulating insulin sensitivity (online appendix Fig. 2). In
contrast, no gene-BMI interaction was observed in modu-
lating either insulinogenic index (adjusted P  0.72) or
disposition index (adjusted P  0.50).
Overweight/obese children. In subjects carrying the KQ
genotype, baseline fasting plasma insulin was higher (ad-
justed P  1.5  10
2) than in KK individuals (Table 1).
Although not reaching a nominal statistical signiﬁcance
with the present sample size (P  0.21), plasma glucose
levels during OGTT tended to be different across K121Q
genotype groups, with QQ individuals showing the worst
proﬁle (Fig. 2A). Plasma insulin levels during OGTT were
different across genotypes (adjusted overall P value 3.5 
10
3) and higher, at post hoc analysis, in KQ than in KK
subjects (adjusted P  2.4  10
3) (Fig. 2B). Insulin
secretion and sensitivity data obtained in this sample were
very similar to those observed in adults, with QQ individ-
uals showing, compared with KQ and KK subjects, a
reduced insulinogenic index (P  7  10
3 and 2  10
2,
respectively) (Fig. 2C) and disposition index (P  2  10
2
and 7  10
3, respectively) (Fig. 2E).
DISCUSSION
Here, we report that adult whites carrying the ENPP1
Q121 variant show altered glucose homeostasis during
OGTT due to an inefﬁcient interplay between insulin
secretion and insulin sensitivity (i.e., a reduced disposition
index). In hyperglycemic individuals, disposition index
TABLE 1
Subjects clinical features and fasting biochemical parameters according to the ENPP1 K121Q polymorphism
Adult subjects (n  764) Children (n  240)
KK KQ QQ KK KQ QQ
n (%) 528 (69) 215 (28) 21 (3) 166 (69) 64 (27) 10 (4)
Male/female 186/342 73/142 6/15 67/99 22/42 2/8
Age (years) 37.1  0.53 37.1  0.84 34.5  2.25 12.9  0.22 13.0  0.31 13.4  0.65
BMI (kg/m
2) 35.5  0.46 36.6  0.77 34.4  2.24 — — —
BMI z score (kg/m
2) — — — 2.23  0.03 2.36  0.12 2.30  0.10
Plasma glucose (mmol/l) 5.17  0.03 5.25  0.05 5.47  0.19* 4.97  0.10 4.92  0.10 4.68  0.16
IRI (pmol/l) 85.5  2.32 86.9  3.87 71.9  8.88 124.6  4.70 144.4  8.54† 144.7  23.0
HDL cholesterol (mmol/l) 1.18  0.02 1.17  0.02 1.14  0.07 1.05  0.02 1.02  0.03 0.97  0.12
Triglycerides (mmol/l) 1.29  0.03 1.32  0.05 1.12  0.14 1.02  0.04 0.95  0.06 0.79  0.08
Data are means  SEM unless otherwise indicated. Signiﬁcances are given after adjusting for age, sex, and BMI or BMI z score. *P  1.6 
10
2 vs. KK adults and †P  1.5  10
2 vs. KK children and adolescents. IRI, immunoreactive insulin.
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insulin resistance, or both. Our data show that QQ carriers
have impaired ﬁrst-phase insulin secretion, which entirely
account for their reduced disposition index. Conversely,
the reduction of disposition index in KQ subjects, who
have a perfectly normal ﬁrst-phase insulin secretion, is
entirely due to insulin resistance. The insulin sensitivity
index was not reduced in QQ individuals as a whole. It
should be considered that insulin resistance inferred from
increased endogenous insulin levels (as done in our case)
may be underestimated in individuals with reduced insulin
secretion such as QQ carriers seem to be. We observed a
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FIG. 1. Glucose, insulin, and derived indexes at OGTT in adult subjects. Glucose (A) and insulin (B) levels during OGTT in QQ (black triangles),
KQ (gray circles), and KK (white circles) adult individuals. Insulinogenic index (C), insulin sensitivity index (ISI) (D), and disposition index (E)
values in QQ (black bar), KQ (gray bar), and KK (white bar) adult individuals. All data were adjusted for sex, age, and BMI. A: Plasma glucose
proﬁles in QQ vs. KK carriers, *P  5  10
2. B: Plasma insulin levels at 30 min in QQ vs. KQ (†P  2  10
4) and vs. KK carriers (‡P  4  10
5).
C: QQ vs. KQ carriers, §P  3.2  10
6; QQ vs. KK carriers, P  2.2  10
7. D: KQ vs. KK carriers, ¶P  3.6  10
2. E: KQ vs. KK carriers, #P 
3  10
2; QQ vs. KK carriers,
**P  4  10
4; QQ vs. KQ carriers, ††P  8  10
3.
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FIG. 2. Glucose, insulin, and derived indexes at OGTT in children. Glucose (A) and insulin (B) levels during OGTT in QQ (black triangles), KQ
(gray circles), and KK (white circles) individuals. Insulinogenic index (C), insulin sensitivity index (ISI) (D), and disposition index (E)i nK K
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3. C: QQ vs. KQ carriers, †P  7  10
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E: QQ vs. KQ carriers, P  2  10
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3.
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lin sensitivity, which is in line with other evidence showing
such interaction in modulating the risk of hyperinsulin-
emia (14), atherosclerosis (15), and type 2 diabetes
(16,17). Based on the linear slopes indicating the relation-
ships between insulin sensitivity index and BMI across
genotype groups, it appears that QQ individuals tend to
have a reduced insulin sensitivity index among frankly
obese, but not among lean, subjects. This may be due to
the protective role of the QQ genotype on BMI (18), which,
when successfully operating (as it is in lean individuals), is
likely to preserve insulin sensitivity. We hypothesize that
among lean individuals, in the absence of a coexistent
reduction of insulin sensitivity, the defective ﬁrst-phase
insulin secretion observed in QQ individuals is not sufﬁ-
cient by itself to increase the risk of type 2 diabetes. In
contrast, in the presence of an obesogenic background,
the deleterious effect of the Q121 variant on insulin
secretion is added on top of that exerted on insulin
sensitivity, thus eventually increasing the risk of type 2
diabetes.
Overall, the novel ﬁndings of our study are that 1) the
ENPP1 Q121 variant affects insulin secretion; 2) for this
effect to be evident, the homozygous state is necessary;
and 3) the homozygous state is also necessary for a strong
deleterious effect on glucose homeostasis and disposition
index, which, in fact, are signiﬁcantly worse in QQ than in
KQ subjects. These data perfectly ﬁt with, and possibly
explain, the increased risk of type 2 diabetes of QQ (but
not KQ) individuals described by a large meta-analysis
comprising all studies thus far published in whites (10).
Our ﬁndings suggest a role of altered insulin signaling in
increasing the risk of type 2 diabetes as well as having a
direct negative effect on -cell function (19). As a matter of
fact, cultured -cells and animals with deﬁcient insulin
receptors (20) or insulin receptor substrate-1 (IRS-1) (21)
have reduced insulin secretion. This defect is mainly
mediated by the impaired insulin stimulation of the down-
stream phosphatidylinositol 3-kinase (PI3-K) activity,
which alters vesicle trafﬁcking (22) and the release of
intracellular calcium stores (21). Insulin stimulation of
insulin receptors (7,9), IRS-1 (7), and PI3-K (7) activation
is clearly reduced in nonpancreatic cells carrying the Q121
variant. Thus, although the suggestion is entirely specula-
tive, altered -cell function in Q121 carriers might be
secondary to defective activation of the insulin receptor/
IRS-1/PI3-K signaling pathway.
A second important ﬁnding of our study is that reduced
ﬁrst-phase insulin secretion and the inefﬁcient interplay
between insulin secretion and sensitivity occur at early
ages in obese QQ individuals. Although children of normal
weight would have been an interesting group to examine
in order to investigate the role of the Q121 variant on
glucose homeostasis, our present ﬁnding is, nonetheless,
of clinical importance given the recent emergence of
hyperglycemia in the early stage of life (23).
The rs7767502 single nucleotide polymorphism, which is
in perfect linkage disequilibrium with K121Q (r
2  1), was
not associated with either the insulinogenic index or the
homeostasis model assessment of insulin resistance index
(P  0.47 and 0.34, respectively) among Scandinavians in
the Diabetes Genetics Initiative (DGI) (http://www.broad.
mit.edu/diabetes) (24). Several factors may underlie this
apparent discrepancy. First, the DGI did not evaluate the
recessive genetic model, which is clearly accounting for
defective insulin secretion in our population. In addition,
some heterogeneity in the diabetogenic effect of the Q121
variant has been reported among whites (10). A similar
heterogeneity among Europeans has also been reported
for the peroxisome proliferator–activated receptor 	
(PPAR) P12A polymorphism, a well-established genetic
marker of type 2 diabetes (25). Thus, a population speciﬁc
effect cannot be excluded a priori and should be formally
tested in further multicenter studies. Unfortunately, nei-
ther insulin sensitivity index nor disposition index values
are available in the DGI database.
The risk of false positive results can affect the genetic
investigation of complex traits. Thus, despite the strong P
values observed (i.e., in the range of the genome-wide
signiﬁcance for glucose proﬁles and early insulin secre-
tion), the very similar results obtained in a cohort of
overweight/obese children, the genetic homogeneity of the
samples studied (12), and the clear consistency with the
risk of type 2 diabetes reported in QQ individuals (10)
render unlikely a false positive result. Our present ﬁndings
have to be formally replicated in independent cohorts
before they can be considered deﬁnitive.
In conclusion, carriers of the ENPP1 Q121 variant,
especially in the homozygous state, show altered glucose
homeostasis. Reduced ﬁrst-phase insulin secretion and an
inefﬁcient interplay between insulin secretion and sensi-
tivity, which occur at early ages, are major determinants of
this defect and are likely to play a role also in the
increased risk of type 2 diabetes displayed by these
individuals (10).
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